Well, IMO two big problems
1. Underfunded for the vascular patches and underestimated the difficulties achieving market share
2. Wrong bet on antiviral immunotherapy
That's what nearly killed the company and brought the share price crashing down by 90% (or more).
Not sure about lessons learned, simple survival tactics.
FNN Presentation .. WOW!, page-131
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.17 |
Change
-0.230(1.49%) |
Mkt cap ! $319.3M | |||
| Open | High | Low | Value | Volume |
| $15.15 | $15.39 | $15.00 | $103.1K | 6.823K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4 | $15.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 147 | 3 |
View Market Depth
| Last trade - 15.11pm 22/08/2024 (20 minute delay) ? |
| AVR (ASX) Chart |